Methods for Identifying a Patient as a Candidate for Treatment with a Long Acting Beta Agonist and for Predicting a Patient's Response to Long Acting Beta2 Agonist Therapy by Analysing Polymorphisms in the Beta2-Adrenergic Receptor Gene
AssigneeAstraZeneca AB
InventorsHelen Jean Ambrose, Mitchell Joel Goldman
Life of this patent
Estimating the term…
Abstract
A method for identifying a patient as a candidate for treatment with a long acting beta agonist comprises isolating a biological sample from a patient and identifying the presence or absence of at least one haplotype C. The presence of at least one haplotype C in a patient sample indicates that the patient is a good candidate for treatment. For example, the patient may have a respiratory disease such as an obstructive airway disease.
Claims9
A method for identifying a patient as a candidate for treatment with a long acting beta agonist comprising:
- a) isolating a biological sample from a patient;
- b) identifying in said sample the presence or absence of at least one haplotype C;
- wherein the presence of at least one haplotype C in a patient sample indicates that the patient is a good candidate for treatment.
A method for predicting an asthma patient's response to the long acting β2 agonist therapy comprising detecting the genotype for the patient at nucleotides BUP, 16 and 27 of the coding sequence for ADRB2 wherein the patient is likely to exhibit a good response to a standard dose of the long acting β2 agonist if the patient has Cys (BUP), Gly16 and Gln 27.
An isolated nucleic acid molecule comprising a sequence of any one of the oligonucleotide probes set out in Table 2.
Dependencies are inferred from the claim text.